Developing New Agents for Inflammation and Obesity, and Its Related Disease
A special issue of Biomedicines (ISSN 2227-9059). This special issue belongs to the section "Molecular and Translational Medicine".
Deadline for manuscript submissions: closed (31 August 2022) | Viewed by 4367
Special Issue Editor
Interests: insulin resistance; inflammation; macrophage; obesity-induced insulin resistance; developing new agents for obesity, insulin resistance and metabolic syndrome
Special Issue Information
Dear Colleagues,
The obesity epidemic has become an alarming, substantial public health crisis. Obesity is widely accepted as an inflammatory disease, and obesity-related diseases, such as dyslipidemia, steatohepatitis, type 2 diabetes mellitus, and cardiovascular diseases, share common characteristics of inflammation. Based on this knowledge, inflammation has become a major target of new drugs to fight obesity and obesity-related diseases.
This Special Issue aims to focus on recent advances in clinical or preclinical research of obesity and inflammation, and in developing new agents, including natural products, for inflammation and obesity, and its related disease. We also welcome all kinds of research describing obesity and inflammation-related disease, as well as natural compounds.
Dr. Byung-Cheol Lee
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Biomedicines is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- obesity
- inflammation
- drug development
- natural compounds
- bioactive peptides
Benefits of Publishing in a Special Issue
- Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
- Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
- Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
- External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
- e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.
Further information on MDPI's Special Issue policies can be found here.
